ESR1 and breast carcinoma: Although patients with ER expressing (ER+) tumors are responsive to hormonal therapy, most ER + breast cancer patients may eventually develop resistance to hormonal therapies; on the other hand, ER- tumors are more aggressive and unresponsive to estrogen-targeted hormonal therapy [2].